Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Autoimmune hepatitis (AIH) is an immune-mediated disease with no curative treatment. Regulatory T cell (Treg) therapy is potentially curative in AIH given the critical role of Tregs in preventing autoimmunity. To work effectively, adoptively transferred Tregs must migrate to and survive within the inflamed liver. We conducted a proof-of-concept study aiming to assess the safety and liver-homing properties of good manufacturing practice (GMP)-grade autologous Tregs in patients with AIH. METHODS: Autologous polyclonal GMP-grade Tregs were isolated using leukapheresis and CliniMACS, labelled with indium tropolonate and re-infused intravenously to 4 patients with AIH. GMP-Treg homing to the liver was investigated with longitudinal gamma camera and SPECT-CT scanning. GMP-Treg immunophenotype, function and immunometabolic state were assessed during the study. RESULTS: We observed that the isolated Tregs were suppressive and expressed CXCR3, a chemokine receptor involved in recruitment into the inflamed liver, as well as Treg functional markers CD39, CTLA-4 and the transcription factor Foxp3. Serial gamma camera and SPECT-CT imaging demonstrated that 22-44% of infused Tregs homed to and were retained in the livers of patients with autoimmune hepatitis for up to 72 h. The infused cells did not localise to any off-target organs other than the spleen and bone marrow. GMP-Tregs were metabolically competent and there were no infusion reactions or high-grade adverse effects after Treg infusion. CONCLUSION: Our novel findings suggest that the liver is a good target organ for Treg cellular therapy, supporting the development of clinical trials to test efficacy in autoimmune hepatitis and other autoimmune liver diseases. LAY SUMMARY: Autoimmune liver diseases occur when the body's immune cells target their own liver cells. Regulatory T cells (Tregs) prevent autoimmunity, thus they are a potential therapy for autoimmune liver diseases. In patients with autoimmune hepatitis, Treg infusion is safe, with nearly a quarter of infused Tregs homing to the liver and suppressing tissue-damaging effector T cells. Thus, Tregs are a potentially curative immune cell therapy for early autoimmune liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669 · cited 1×
“Tregs are a subset of CD4 T cells that maintain peripheral immune homeostasis by suppressing a range of effector immune responses to allow immune resolution and establish homeostatic balance between immune activation and tolerance.(8,9) In 1995, Sakaguchi and colleagues showed by adoptive transfer that subsets of CD4…”
BackgroundSeddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060468 · Cited by 1,512 · cited 1×
“correlates inversely with Foxp3 and Treg suppressive function; hence Tregs are now defined as CD4CD25CD127Foxp3 cells.(12) Failure of Tregs to suppress effector cells is a typical feature of autoimmunity, including AIH, leading to studies exploring the use of either polyclonal(13,14) or antigen-specific Tregs as cellu…”
BackgroundType 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033 · cited 2×
“This period was long enough to exclude a transient trapping in the liver sinusoids but future studies, using for example deuterium labelled cells, will allow us to study longer term tissue residency and stability.(13) Ideallywewould have carried out post-infusion liver biopsies to study the infused Tregs in the liverm…”
BackgroundMarek-Trzonkowska, N., Myśliwiec, M., Dobyszuk, A., Grabowska, M., Techmańska, I., Juścińska, J., Wujtewicz, M. A., Witkowski, P., Młynarski, W., Balcerska, A., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0038 · Cited by 431
Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1
de Boer, Y. S., van Gerven, N. M. F., Zwiers, A., Verwer, B. J., van Hoek, B., van Erpecum, K. J., Beuers, U., van Buuren, H. R., Drenth, J. P. H., den Ouden, J. W., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.022 · Cited by 304
Cited by
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Metabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
The liver as a central "hub" of the immune system: pathophysiological implications
Ronca, V., Gerussi, A., Collins, P., Parente, A., Oo, Y. H., & Invernizzi, P. (2025) · Physiological Reviews · doi:10.1152/physrev.00004.2023 · Cited by 59
Self-citationFunctional heterogeneity of CD4+ T cells in liver inflammation
Muscate, F., Woestemeier, A., & Gagliani, N. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00881-w · Cited by 32
Expression of E-cadherin by CD8+ T cells promotes their invasion into biliary epithelial cells
Davies, S. P., Ronca, V., Wootton, G. E., Krajewska, N. M., Bozward, A. G., Fiancette, R., Patten, D. A., Yankouskaya, K., Reynolds, G. M., Pat, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44910-2 · Cited by 25
Self-citationThe immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects
Ronca, V., Davies, S. P., Oo, Y. H., & Lleo, A. (2025) · Hepatology · doi:10.1097/hep.0000000000001225 · Cited by 22
Self-citationMechanisms of autoimmune hepatitis
Cardon, A., Conchon, S., & Renand, A. (2021) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000704 · Cited by 18
Regulatory T cell stability determines the efficiency of bile duct regeneration during cholangitis
Kimura, N., Wong, M. C., Hardisty, G., Higgins, B., Huang, P.-C., Besh, M., Patten, D. A., Kendall, T., Ramachandran, P., Rossi, A. G., et al. (2025) · doi:10.1101/2025.04.02.646748 · Cited by 3
Metadata
- Authors
- Oo, Y. H., Ackrill, S., Cole, R., Jenkins, L., Anderson, P., Jeffery, H. C., Jones, N., Jeffery, L. E., Lutz, P., Wawman, R. E., Athwal, A. K., Thompson, J., Gray, J., Guo, K., Barton, D., Hirschfield, G. M., Wong, T., Guest, P., & Adams, D. H.
- Venue
- JHEP Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 1
- Issue
- 4
- Pages
- 286-296
- ISSN
- 2589-5559 (ISSN-L)
- OpenAlex
- W2969771043
- Cited by
- 79
- References
- 5
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.